At the power levels available for the present sample sizes, there were no statistically significant differences in the prevalences of each of the four types of MSDs in participants with 22q compared with prevalence estimates in participants with DS, FXS, and GAL assessed with the same measures. The gene discussed is GAL; the disease is fragile X syndrome.